A systematic review and meta-analysis of the effectiveness of hypertension interventions in faith-based organisation settings.


Journal

Journal of global health
ISSN: 2047-2986
Titre abrégé: J Glob Health
Pays: Scotland
ID NLM: 101578780

Informations de publication

Date de publication:
13 Oct 2023
Historique:
medline: 1 11 2023
pubmed: 13 10 2023
entrez: 13 10 2023
Statut: epublish

Résumé

Hypertension is the global, leading cause of mortality and is the main risk factor for cardiovascular disease. Community-based partnerships can provide cost-saving ways of delivering effective blood pressure (BP) interventions to people in resource-poor settings. Faith-based organisations (FBOs) prove important potential health partners, given their reach and community standing. This potential is especially strong in hard-to-reach, socio-economically marginalised communities. This systematic review explores the state of the evidence of FBO-based interventions on BP management, with a focus on randomised controlled trials (RCTs) and cluster RCTs (C-RCTs). Seven academic databases (English = 5, Chinese = 2) and grey literature were searched for C-/RCTs of community-based interventions in FBO settings. Only studies with pre- and post-intervention BP measures were kept for analysis. Random effects models were developed using restricted maximum likelihood estimation (REML) to estimate the population average mean change and 95% confidence interval (CI) of both systolic and diastolic blood pressure (SBP and DBP). The overall heterogeneity was assessed by successively adding studies and recording changes in heterogeneity. Prediction intervals were generated to capture the spread of the pooled effect across study settings. Of the 19 055 titles identified, only 11 studies of fair to good quality were kept for meta-analysis. Non-significant, average mean differences between baseline and follow-up for the intervention and control groups were found for both SBP (0.78 mm of mercury (mmHg) (95% CI = 2.11-0.55)) and DBP (-0.20 mm Hg (95% CI = -1.16 to 0.75)). Subgroup analysis revealed a significant reduction in SBP of -6.23 mm Hg (95% CI = -11.21 to -1.25) for populations with mean baseline SBP of ≥140 mm Hg. The results support the potential of FBO-based interventions in lowering SBP in clinically hypertensive populations. However, the limited evidence was concentrated primarily in Christian communities in the US More research is needed to understand the implications of such interventions in producing clinically meaningful long-term effects in a variety of settings. Further research can illuminate factors that affect success and potential expansion to sites outside the US as well as non-Christian FBOs. Current evidence is inadequate to evaluate the potential of FBO-based interventions in preventing hypertension in non-hypertensive populations. Intervention effects in non-hypertensive population might be better reflected through intermediate outcomes.

Sections du résumé

Background UNASSIGNED
Hypertension is the global, leading cause of mortality and is the main risk factor for cardiovascular disease. Community-based partnerships can provide cost-saving ways of delivering effective blood pressure (BP) interventions to people in resource-poor settings. Faith-based organisations (FBOs) prove important potential health partners, given their reach and community standing. This potential is especially strong in hard-to-reach, socio-economically marginalised communities. This systematic review explores the state of the evidence of FBO-based interventions on BP management, with a focus on randomised controlled trials (RCTs) and cluster RCTs (C-RCTs).
Methods UNASSIGNED
Seven academic databases (English = 5, Chinese = 2) and grey literature were searched for C-/RCTs of community-based interventions in FBO settings. Only studies with pre- and post-intervention BP measures were kept for analysis. Random effects models were developed using restricted maximum likelihood estimation (REML) to estimate the population average mean change and 95% confidence interval (CI) of both systolic and diastolic blood pressure (SBP and DBP). The overall heterogeneity was assessed by successively adding studies and recording changes in heterogeneity. Prediction intervals were generated to capture the spread of the pooled effect across study settings.
Results UNASSIGNED
Of the 19 055 titles identified, only 11 studies of fair to good quality were kept for meta-analysis. Non-significant, average mean differences between baseline and follow-up for the intervention and control groups were found for both SBP (0.78 mm of mercury (mmHg) (95% CI = 2.11-0.55)) and DBP (-0.20 mm Hg (95% CI = -1.16 to 0.75)). Subgroup analysis revealed a significant reduction in SBP of -6.23 mm Hg (95% CI = -11.21 to -1.25) for populations with mean baseline SBP of ≥140 mm Hg.
Conclusions UNASSIGNED
The results support the potential of FBO-based interventions in lowering SBP in clinically hypertensive populations. However, the limited evidence was concentrated primarily in Christian communities in the US More research is needed to understand the implications of such interventions in producing clinically meaningful long-term effects in a variety of settings. Further research can illuminate factors that affect success and potential expansion to sites outside the US as well as non-Christian FBOs. Current evidence is inadequate to evaluate the potential of FBO-based interventions in preventing hypertension in non-hypertensive populations. Intervention effects in non-hypertensive population might be better reflected through intermediate outcomes.

Identifiants

pubmed: 37830137
doi: 10.7189/jogh.13.04075
pmc: PMC10570758
doi:

Types de publication

Meta-Analysis Systematic Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

04075

Informations de copyright

Copyright © 2023 by the Journal of Global Health. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure of interest: The authors completed the ICMJE Disclosure of Interest Form (available upon request from the corresponding author) and disclose no relevant interests.

Références

BMJ Open. 2015 Jun 30;5(6):e007571
pubmed: 26129635
Circ Cardiovasc Qual Outcomes. 2018 Oct;11(10):e004691
pubmed: 30354579
J Health Care Poor Underserved. 2019;30(1):80-101
pubmed: 30827971
Lancet Glob Health. 2019 Jun;7(6):e761-e771
pubmed: 31097278
EClinicalMedicine. 2022 Apr 15;47:101388
pubmed: 35480075
Am J Prev Med. 2013 Feb;44(2):122-31
pubmed: 23332327
Health Behav Policy Rev. 2020 Jul;7(4):279-291
pubmed: 32864386
BMJ Open. 2022 Feb 09;12(2):e060387
pubmed: 35140165
Hypertension. 2020 Jul;76(1):217-225
pubmed: 32450739
J Med Virol. 2020 Jun;92(6):577-583
pubmed: 32162702
Lancet. 2018 Nov 10;392(10159):1923-1994
pubmed: 30496105
Circulation. 2015 Sep 1;132(9):815-24
pubmed: 26187183
Eur J Intern Med. 2020 Dec;82:1-6
pubmed: 32972800
J Med Internet Res. 2020 May 20;22(5):e16019
pubmed: 32432556
PLoS One. 2017 Jul 13;12(7):e0180640
pubmed: 28704405
Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1289-1297
pubmed: 30337343
J Am Geriatr Soc. 2010 Oct;58(10):1863-9
pubmed: 20929464
JAMA. 2017 Sep 19;318(11):1016-1025
pubmed: 28975305
J Hypertens. 2015 Feb;33(2):221-9
pubmed: 25479029
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Hypertension. 2021 Sep;78(4):955-965
pubmed: 34397275
Lancet. 2019 Oct 5;394(10205):1231-1242
pubmed: 31488369
Public Health Rep. 2001;116 Suppl 1:68-81
pubmed: 11889276
Front Public Health. 2022 May 31;10:896603
pubmed: 35712306
Ann Fam Med. 2004 May-Jun;2(3):204-8
pubmed: 15209195
Stroke. 2015 Oct;46(10):2861-7
pubmed: 26374480
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Lancet. 2015 Oct 31;386(10005):1765-75
pubmed: 26159398
Lancet. 2008 Nov 29;372(9653):1865-1867
pubmed: 18930539
Soc Sci Med. 2021 Dec;291:114473
pubmed: 34662762
JAMA Netw Open. 2019 Dec 2;2(12):e1916545
pubmed: 31790570
Lancet. 2014 May 31;383(9932):1899-911
pubmed: 24881994
Curr Cardiol Rep. 2020 Jun 19;22(8):64
pubmed: 32562103
Lancet. 2015 Oct 31;386(10005):1786-94
pubmed: 26159394
Hypertension. 2018 Jun;71(6):1269-1324
pubmed: 29133354
Cochrane Database Syst Rev. 2015 Aug 04;(8):CD011163
pubmed: 26272648
Lancet Glob Health. 2019 Jun;7(6):e686-e687
pubmed: 31097265
Prev Chronic Dis. 2019 Aug 08;16:E106
pubmed: 31400096
J Med Internet Res. 2018 Aug 24;20(8):e256
pubmed: 30143478
Diabetes Educ. 2009 May-Jun;35(3):439-54
pubmed: 19383882
Int J Epidemiol. 2001 Aug;30(4):734-7
pubmed: 11511594
BMC Med. 2020 Nov 18;18(1):338
pubmed: 33203396

Auteurs

Kit Yee Chan (KY)

Centre for Global Health, Usher Institute, University of Edinburgh, Edinburgh, UK.
School of Social Sciences, Monash University, Clayton, Victoria, Australia.

Noori Srivastava (N)

Department of Medicine, School of Medicine & Health Sciences, George Washington University, Washington DC, USA.

Zhicheng Wang (Z)

China Development Research Foundation, Beijing, China.

Xiaoqian Xia (X)

London School of Hygiene & Tropical Medicine, London, UK.

Zhangziyue Huang (Z)

Milken Institute School of Public Health, George Washington University, Washington DC, USA.

Adrienne N Poon (AN)

Department of Medicine, School of Medicine & Health Sciences, George Washington University, Washington DC, USA.

Daniel D Reidpath (DD)

School of Social Sciences, Monash University, Clayton, Victoria, Australia.
Institute for Global Health and Development, Queen Margaret University, Edinburgh, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH